# Kymab

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kymab

- Industry: Pharmaceuticals
- Headquarters: Cambridge, UK
- Website: www.kymab.com
- Total disclosed funding: $101M
- Latest round: Series C (Nov 24, 2016)
- Investors on record: 6

## About

Kymab Ltd. is a biopharmaceutical company focused on the development of innovative therapeutic antibodies to address critical unmet medical needs, particularly in autoimmune diseases and cancer.Founded in 2010 in Cambridge, UK, Kymab Ltd. specializes in the discovery and development of monoclonal antibodies. The company has completed 6 deals, with its most recent being a TRADE SALE to Sanofi S.A. in January 2021, which involved an upfront payment of approximately USD 1.1 bn and potential milestone payments of up to USD 350 mn. Simon Sturge serves as the CEO.Kymab specializes in the development and commercialization of innovative therapeutic antibodies aimed at addressing significant unmet medical needs. The company’s core product offerings include monoclonal antibodies that leverage its proprietary technologies to enhance drug efficacy and safety. These therapeutics are particularly focused on treating autoimmune diseases and cancer, with the goal of improving patient outcomes through targeted action. Kymab has built a diverse client base that includes pharmaceutical companies and research institutions, primarily serving markets in North America and Europe. The company’s products are designed to provide advanced treatment options for healthcare providers and patients, ultimately aiming to bring novel solutions to complex medical challenges.In 2023, Kymab reported a revenue of USD 1,762,656.10 with an EBITDA of USD -221,375,672.20. The company's revenue model largely relies on strategic partnerships and collaborations with industry leaders, involving licensing agreements that provide milestone payments and royalties tied to the success of therapeutic candidates.Kymab intends to leverage its recent TRADE SALE deal with Sanofi S.A. for funding future product development and clinical trials. The transaction, which was announced in January 2021, is expected to be finalized in the first half of 2021. The company is also looking to expand its market presence in North America and Europe, focusing on the introduction of new therapeutic candidates that are currently in development.

## Funding rounds

- Series C, Nov 24, 2016, $101M — Wellcome Trust, Bill & Melinda Gates Foundation, Woodford Patient Capital Trust, Shenzhen Hepalink Pharmaceutical Group, Malin Corporation, ORI Capital

## Investors

- Wellcome Trust — Series C
- Bill & Melinda Gates Foundation — Series C
- Woodford Patient Capital Trust — Series C
- Shenzhen Hepalink Pharmaceutical Group — Series C
- Malin Corporation — Series C
- ORI Capital (https://capitalatlas.ai/funds/ori-capital) — Series C